{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000025","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.166824+00:00","generated_at":"2026-06-04T01:49:23.315000+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR","bullets":["68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.","Majority of patients showed antigen spreading: T cells targeted additional patient-specific tumor mutations beyond mKRAS.","Booster doses maintained/increased mKRAS-specific T cell response with increased memory phenotype; no regulatory T cell response detected.","Preclinical ELI-007 and ELI-008 showed 42-fold to several-hundred-fold increased immune response vs. conventional vaccines.","Initial clinical data for ELI-002 7P expected in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000025","json":"https://secwatch.observer/filing/0001601485-24-000025.json","markdown":"https://secwatch.observer/filing/0001601485-24-000025.md","text":"https://secwatch.observer/filing/0001601485-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/0001601485-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000025/angn-20240405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:49:23.315000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}